Valeant Pharmaceuticals International Inc., which in recent months has been under fire for its pricing, was among the most aggressive, with 13 drugs that doubled or more in price. That is more than any other large company, the survey found. The heart drug Isuprel soared 720 percent over the period, including 525 percent right after Valeant bought the rights to sell it.